Hepion Pharmaceuticals Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 2

Employees

  • Stock Symbol
  • HEPA

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.11
  • (As of Friday Closing)

Hepion Pharmaceuticals General Information

Description

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of drug therapy for the treatment of chronic liver diseases. The company is pioneering early cancer detection solutions with a novel liquid biopsy. diagnostics. The company's mission is to redefine the early detection of hepatocellular carcinoma, moving from missed diagnoses to timely, precise intervention. It's focused on delivering non-invasive, clinically grounded liquid biopsy solutions for patients at the highest risk, particularly those living with cirrhosis.

Contact Information

Formerly Known As
ContraVir Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 399 Thornall Street
  • 1st Floor
  • Edison, NJ 08837
  • United States
+1 (732)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
OTCM
Vertical(s)
Corporate Office
  • 399 Thornall Street
  • 1st Floor
  • Edison, NJ 08837
  • United States
+1 (732)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hepion Pharmaceuticals Stock Performance

As of 13-Nov-2026, Hepion Pharmaceuticals’s stock price is $0.11. Its current market cap is $14.1M with 123M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.11 $0.14 $0.03 - $0.22 $14.1M 123M 38.8K -$0.19

Hepion Pharmaceuticals Financials Summary

As of 30-Jun-2026, Hepion Pharmaceuticals has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,068 286 5,693 (3,293)
Revenue 0 0 0 0
EBITDA (3,188) (8,253) (14,884) (49,258)
Net Income (3,188) (8,278) (13,192) (48,926)
Total Assets 1,927 3,070 1,614 18,094
Total Debt 0 54 2,900 209
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Hepion Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Hepion Pharmaceuticals‘s full profile, request access.

Request a free trial

Hepion Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of drug therapy for the treatm
Biotechnology
Edison, NJ
2 As of 2025

West Conshohocken, PA
 

Morristown, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Hepion Pharmaceuticals Competitors (2)

One of Hepion Pharmaceuticals’s 2 competitors is Madrigal Pharmaceuticals, a Formerly VC-backed company based in West Conshohocken, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Madrigal Pharmaceuticals Formerly VC-backed West Conshohocken, PA
Intercept Pharmaceuticals Formerly VC-backed Morristown, NJ
You’re viewing 2 of 2 competitors. Get the full list »

Hepion Pharmaceuticals Patents

Hepion Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024285817-A1 Solid state forms of rencofilstat Pending 08-Jun-2023
EP-4724081-A2 Solid state forms of rencofilstat Pending 08-Jun-2023
WO-2024254480-A2 Solid state forms of rencofilstat Inactive 08-Jun-2023
WO-2024254480-A3 Solid state forms of rencofilstat Inactive 08-Jun-2023
AU-2021388171-A1 Use of cyclosporine analogues as antithrombotic agents Pending 29-Nov-2020 A61K38/13
To view Hepion Pharmaceuticals’s complete patent history, request access »

Hepion Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hepion Pharmaceuticals Acquisitions (2)

Hepion Pharmaceuticals’s most recent deal was a Merger/Acquisition with Gravitas Life Sciences. The deal was made on 06-Oct-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Gravitas Life Sciences 06-Oct-2026 Merger/Acquisition Pharmaceuticals
Ciclofilin Pharmaceuticals 10-Jun-2016 Merger/Acquisition Drug Discovery
To view Hepion Pharmaceuticals’s complete acquisitions history, request access »

Hepion Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated March, 31, 2026

43.03 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,271

Rank

Percentile

Pharmaceuticals

Industry

of 908

Rank

Percentile

Pharmaceuticals

Subindustry

of 406

Rank

Percentile

To view Hepion Pharmaceuticals’s complete esg history, request access »

Hepion Pharmaceuticals FAQs

  • When was Hepion Pharmaceuticals founded?

    Hepion Pharmaceuticals was founded in 2013.

  • Where is Hepion Pharmaceuticals headquartered?

    Hepion Pharmaceuticals is headquartered in Edison, NJ.

  • What is the size of Hepion Pharmaceuticals?

    Hepion Pharmaceuticals has 2 total employees.

  • What industry is Hepion Pharmaceuticals in?

    Hepion Pharmaceuticals’s primary industry is Biotechnology.

  • Is Hepion Pharmaceuticals a private or public company?

    Hepion Pharmaceuticals is a Public company.

  • What is Hepion Pharmaceuticals’s stock symbol?

    The ticker symbol for Hepion Pharmaceuticals is HEPA.

  • What is the current stock price of Hepion Pharmaceuticals?

    As of 13-Nov-2026 the stock price of Hepion Pharmaceuticals is $0.11.

  • What is the current market cap of Hepion Pharmaceuticals?

    The current market capitalization of Hepion Pharmaceuticals is $14.1M.

  • Who are Hepion Pharmaceuticals’s competitors?

    Madrigal Pharmaceuticals and Intercept Pharmaceuticals are competitors of Hepion Pharmaceuticals.

  • What is Hepion Pharmaceuticals’s annual earnings per share (EPS)?

    Hepion Pharmaceuticals’s EPS for 12 months was -$0.19.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process